Clinical Trial Update: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]

View source ↗

Summary

Phase 3 study evaluating long-term safety and efficacy of garadacimab (CSL312) as prophylaxis for hereditary angioedema completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Garadacimab (CSL312) (garadacimab)

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED